Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. American Society for Clinical Investigation.
Chicago Style CitationShah, Neil P., Brian J. Skaggs, Susan Branford, Timothy P. Hughes, John M. Nicoll, Ronald L. Paquette, i Charles L. Sawyers. Sequential ABL Kinase Inhibitor Therapy Selects for Compound Drug-resistant BCR-ABL Mutations With Altered Oncogenic Potency. American Society for Clinical Investigation, 2007.
Cita MLAShah, Neil P., et al. Sequential ABL Kinase Inhibitor Therapy Selects for Compound Drug-resistant BCR-ABL Mutations With Altered Oncogenic Potency. American Society for Clinical Investigation, 2007.